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Abstract
Rationale Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD)
has antipsychotic and anxiolytic effects.
Objectives We investigated whether CBD would normalise the neuroendocrine and anxiety responses to stress in clinical high
risk for psychosis (CHR) patients.
Methods Thirty-two CHR patients and 26 healthy controls (HC) took part in the Trier Social Stress Test (TSST) and their serum
cortisol, anxiety and stress associated with public speaking were estimated. Half of the CHR participants were on 600 mg/day of
CBD (CHR-CBD) and half were on placebo (CHR-P) for 1 week.
Results One-way analysis of variance (ANOVA) revealed a significant effect of group (HC, CHR-P, CHR-CBD (p = .005) on
cortisol reactivity as well as a significant (p = .003) linear decrease. The change in cortisol associated with experimental stress
exposure was greatest in HC controls and least in CHR-P patients, with CHR-CBD patients exhibiting an intermediate response.
Planned contrasts revealed that the cortisol reactivity was significantly different in HC compared with CHR-P (p = .003), and in
HC compared with CHR-CBD (p = .014), but was not different between CHR-P and CHR-CBD (p = .70). Across the participant
groups (CHR-P, CHR-CBD and HC), changes in anxiety and experience of public speaking stress (all p’s < .02) were greatest in
the CHR-P and least in the HC, with CHR-CBD participants demonstrating an intermediate level of change.
Conclusions Our findings show that it is worthwhile to design further well powered studies which investigate whether CBDmay
be used to affect cortisol response in clinical high risk for psychosis patients and any effect this may have on symptoms.
Keywords Cannabidiol . Trier Social Stress Test . Ultra-high risk . Psychosis
Introduction
Stress plays a major role in the onset and maintenance of
psychosis (Pruessner et al. 2017). Exposure to stress in early
(Beards et al. 2013) and adult (vanWinkel et al. 2008) life has
been linked to an increased risk for psychosis. The
hypothalamic-pituitary-adrenal (HPA) axis is a key neuroen-
docrine regulatory system mediating the biological response
to stress.
Accumulating evidence suggests that a dysfunction in the
HPA-axis might underlie the psychosis continuum (Pruessner
et al. 2017). A recent review of the evidence (Appiah-Kusi
et al. 2016) suggests that in response to a stressor, patients
with established psychosis and those at clinical high risk
(CHR) for psychosis (Day et al. 2014; Pruessner et al. 2013)
tend to exhibit a blunted cortisol response to both social stress
and awakening. Similarly, evidence has shown that
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individuals at CHR of psychosis also have an impaired psy-
chological response to stress. Another study also found that
impaired tolerance to stress was more predictive of transition
to psychosis than attenuated psychotic symptoms (Yung et al.
2005), showing that the psychological response to stress is an
important predictor for psychosis. While atypical antipsy-
chotics have been shown to reduce elevated diurnal cortisol
levels (Zhang et al. 2005; Cohrs et al. 2006; Mondelli et al.
2010), antipsychotic treatment has not been shown to correct
the blunted cortisol response observed in psychosis (Mondelli
et al. 2010).
The harmful effects of cannabis have been mainly attributed
to the effects of its main psychoactive ingredient, delta-9-
tetrahydrocannabinol (THC), which has been shown under ex-
perimental conditions to induce psychotic and anxiety symp-
toms in healthy individuals (D’Souza et al. 2005) and exacer-
ba te psychot ic symptoms in pa t ien t s wi th pre -
existing psychosis (D’Souza et al. 2005). In contrast,
cannabidiol (CBD), is a safe and well-tolerated (Bergamaschi
et al. 2011a) constituent of cannabis and has antipsychotic
(Iseger and Bossong 2015; Leweke et al. 2012; McGuire
et al. 2017; Bhattacharyya et al. 2010) and anxiolytic
(Bergamaschi et al. 2011b) properties. Importantly, preclinical
evidence suggests that CBD may attenuate the effects of ex-
perimentally induced stress in lab animals following both acute
(Guimarães et al. 1990; Campos and Guimarães 2008;
Gomes et al. 2011; Gomes et al. 2012) and chronic treatments
(Campos et al. 2013). Consistent with this, other data has ac-
cumulated that CBD may also block anxiety symptoms in-
duced by THC (Zuardi et al. 1982) or social stress under ex-
perimental conditions in healthy volunteers (Zuardi et al. 1993)
or patients with social anxiety (Bergamaschi et al. 2011b).
Furthermore, CBD has broadly opposite effects to that of
THC, both at the behavioural and neural levels
(Bhattacharyya et al. 2010; Bhattacharyya et al. 2015;
Bhattacharyya et al. 2012) in healthy volunteers and evidence
from double-blind randomised clinical trials point towards ef-
ficacy as an antipsychotic in patients with established psycho-
sis (Leweke et al. 2012; McGuire et al. 2017). More recently,
we have shown that a single dose of CBD may partially nor-
malise dysfunction in the key neural substrates implicated in
psychosis in CHR patients (Bhattacharyya et al. 2018).
However, whether CBD could attenuate the effects of
stress under experimental conditions in patients with
CHR has never been tested before. This is of particular
importance due to the lack of evidence of a beneficial ef-
fect of currently available antipsychotic treatments on the
dysregulated neuroendocrine stress response. Therefore,
the main objective of the present study was to investigate
whether cannabidiol, a non-psychoactive substance present
in the extract of the cannabis plant, has potential to miti-
gate the harmful effects of exposure to stress under exper-
imental conditions in CHR patients.
Therefore, we investigated whether CHR patients had a
blunted neuroendocrine and exaggerated anxiety response to
acute exposure to social stress compared with healthy con-
trols. Our main aim was to assess whether short-term treat-
ment with CBD would partially normalise the altered acute
neuroendocrine and anxiety response stress exposure in CHR
patients. We hypothesised that relative to healthy controls,
CHR patients under the influence of placebo would display
the most severe alterations in the neuroendocrine and psycho-
logical responses to stress, while CBD treatment would atten-
uate some of these effects such that CHR patients under CBD
would display an intermediate level of stress response.
Method
Participants
Cases consisted of 33 individuals who met the Personal
Assessment and Crisis Evaluation (PACE) CHR criteria
(Yung et al. 1998), recruited from a specialist clinical service
for people at risk for psychosis in South London. Controls
consisted of 26 age (± 3 years) and gender-matched healthy
individuals, who had no history of a mental disorder, screened
negative for psychotic disorder using the Psychosis Screening
Questionnaire (PSQ; details below) (Bebbington and Nayani
1995) and were recruited via advertisement in local websites
from the same geographical area as cases. All procedures
comply with the Helsinki Declaration, as revised in 2008.
Participants were reimbursed for their time and travel ex-
penses. These procedures were approved by Psychiatry,
Nursing and Midwifery Research Ethics Committee at
King’s College, London (Approval number PNM/13/14-22),
and NHS ethics 13/LO/0243. All participants gave written
informed consent before taking part in the study and complet-
ed anonymised questionnaires in private.
Procedure
CHR participants were enrolled in a randomised, placebo-
contro l led , between-groups , double-bl ind s tudy
(Bhattacharyya et al. 2018). Sixteen participants were given
oral 600 mg CBD daily and 16 received identical placebo
capsules (STI Pharmaceuticals, UK). On the eighth day of
the study, participants took part in the Trier Social Stress
Test (TSST). Healthy participants came in for one study ses-
sion and were not in any drug trial. All participants started the
protocol (see Fig. 1) at approximately 10 am (− 60 min) after
eating their breakfast at approximately 8.30 am. The TSST
procedures commenced at approximately 11 am. Healthy par-
ticipants were asked not to use cannabis for 96 h (4 days)
before, alcohol for 24 h before and nicotine for 6 h before
any other recreational drugs (e.g. speed, cocaine) from2weeks
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before the study. CHR participants were asked to abstain from
recreational drugs throughout the trial and to not use alcohol
for 24 h before the procedures and nicotine for 6 h before. All
CHR participants were antipsychotic naive. All participants
had a clean urine drug screen result. Participants also took part
in a short health review to rule out any medical condition
which may affect the endocrine system and also to ensure
the healthy participants had no underlying mental health con-
dition. Contraceptives were allowed. Participants were seated
in a phlebotomy chair and a cannula was then inserted into the
antecubital region of the non-dominant arm. Baseline blood
samples (2 ml) were collected into serum-separating tubes.
The participant then completed the baseline battery of ques-
tionnaires (State Trait Anxiety Inventory; STAI, Self-
Statements during Public Speaking Scale; SSDPS).
After these had been completed (generally at 11 am; − 20-
min time point), the participant took part in the TSST (see
below). Following this, participants were led back to the phle-
botomy chair by the experimenter. Blood samples were ob-
tained immediately and then serial questionnaires (STAI,
SSDPS) were filled out (0 min). This same battery of ques-
tionnaires and samples were then also completed at + 10 and
+ 20 min after completing the task. At the end of the session,
participants were debriefed about the study and received re-
imbursement for their participation.
Trier Social Stress Test
The Trier Social Stress Test (TSST) (Kirschbaum et al. 1993)
is a well-validated stress induction paradigm that has been
shown to reliably induce stress as reflected in changes in cor-
tisol levels, under experimental conditions over the past cou-
ple of decades. This stress induction paradigm involves a so-
cial evaluative element, which make it comparable to the so-
cial stressors which individuals experience in their daily lives
and arguably ecologically more valid. Participants were told
they will take part in a public speaking exercise. The experi-
menter takes the participant into a separate room where a
panel of two people were assembled and the standardised
TSST instructions were read to them (see additional
materials; see Fig. 1 for explanation of timing of
procedures). They were then taken to a different room for
the 10-min preparation period. They were informed that they
would be given 10 min to prepare for a 5-min speech where
they had to imagine they had an interview for their ideal job
and they needed to deliver the speech to convince the
panellists as to why they were ideal for that job, they were
then led to an empty room to prepare. After the 10-min prep-
aration period in a different room, participants returned to the
panel to deliver their speech. Once they had completed the
speech, they were informed they would take part in a mental
arithmetic task as per the TSST protocol (see additional ma-
terials for details of mental arithmetic task).
Assessment of endocrine response to stress (primary
outcome)
As illustrated in Fig. 1, neuroendocrine response to stress was
indexed by measuring serum cortisol level in blood samples
collected at baseline (− 60 min) and at 0, +10 and + 20 min
after the Trier Social Stress Test (TSST).
Assessment of anxiety and negative thoughts
about TSST in response to stress
Anxiety was assessed using the State Trait Anxiety Inventory
(STAI) (Spielberger et al. 1970). We employed the ‘state’
subscale of the questionnaire to measure change in anxiety
induced by experimental exposure to stress (STAI-S).
Reactions to public speaking were measured using the Self-
Statements during Public Speaking Scale (SSDPS) (Hofmann
and DiBartolo 2000). This measures individuals’ perception
of performance in relation to public speaking. It has 5 items
evaluating negative thoughts and 5 evaluating positive
thoughts, each rated on a 5-point Likert scale. We employed
the negative subscale for this study. Both of these scales were
collected at baseline (− 60 min) and at 0, + 10 and + 20 min
after the Trier Social Stress Test (TSST).
Statistical analysis
All statistical analyses were carried out using Statistical
Package for Social Science (SPSS) version 22, and the out-
come variables were normally distributed. T tests were carried
out to assess whether there were group differences in sex or
mean age. As there were no differences, neither were
TSST 
Preparaon
TSST 
Delivery
Fig. 1 Timing of procedures for TSST
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considered in the analyses. For the outcome variables of anx-
iety and negative self-statements, area under the curve (AUC)
for the four time points was calculated by using the trapezoid
formula with respect to ground, as outlined by Pruessner et al.
(2003) and these were used in subsequent analyses. For corti-
sol, the change in cortisol level from baseline to the immediate
post-TSST time point (time 0; time 0 minus baseline) was
used in subsequent analyses. In accordance with our hypoth-
esis, separate one-way analysis of variances (ANOVAs) were
carried out with planned linear contrast to examine whether
there was a main effect of group (HC, CHR-CBD, CHR-P)
such that changes were HC > CHR-CBD >CHR-P for each of
the main outcomes of interest (cortisol, anxiety and negative
self-statements).
Missing data
Data for one item in the baseline STAI questionnaire was
missing in one HC participant and for one HC participant in
the baseline SSDPS-N. Similarly, data for one item in the
SSDPS-N questionnaire for the 0-min time point was missing
in two CHR-CBD participants and one CHR-P, and in one
CHR-P participant for the STAI scale at the + 10 time point.
In the case of missing values in questionnaires, an average of
the scale or subscale score was estimated per participant and
used in place of the missing value.
In the case of missing data for outcomes that were mea-
sured repeatedly, the last observation carried forward method
was used to impute missing values. This was used in three
instances of missing data in HC and once in CHR-P for the
SSDPS-N and once for CHR-P for cortisol.
Some participants had incomplete data for the different
time points and could not realistically be transposed and were
therefore not entered into certain analyses. In the cortisol anal-
ysis, this occurred in one CHR-CBD participant. For the STAI
analysis, this occurred in four healthy controls, five CHR-P
participants and two CHR-CBD participants. For the SSDPS-
N analysis, this occurred in three healthy controls, five CHR-P
participants and two CHR-CBD participants.
Results
All results are reported as two-tailed tests. One healthy partic-
ipant was excluded from the analysis as at the time of the
baseline assessment, they met criteria for possible psychotic
disorder. Table 1 outlines the participants’ demographic infor-
mation as well as baseline psychopathology. This outlines that
CHR participants had more cannabis use than healthy controls
at baseline but that cannabis use rates were the same between
the Placebo and CBD groups. There was also no difference
between the two CHR groups on cortisol, STAI and
CAARMS positive scores but STAI was significantly higher Ta
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in CHR compared with healthy control participants.
Furthermore, there was no significant difference in cortisol
levels between the three groups. Healthy controls had a higher
level of education than both CHR groups. There was no dif-
ference in educational level between CBD and placebo
groups. In the CHR-CBD group, on the day of the experiment,
mean plasma CBD levels were 61.0 nM (s.d. = 45.49) about
an hour before TSSTcommenced and 74.71 nM (s.d. = 43.65)
about 40 min after TSST commenced (which was after TSST
was complete).
Table 2 outlines the descriptive statistics for each time point
for all of the measures of response to stress.
Cortisol reactions to TSST
There was a significant effect of group (HC, CHR-P, CHR
cannabidiol; CBD F(2,54) = 5.78, p = .005) on cortisol reac-
tivity (measured as the change in the level of cortisol at 0 min
relative to baseline; − 60 min). Across the three participant
groups, there was a significant F(1,54) = 9.46, p = .003 linear
decrease in cortisol reactivity, such that the change in cortisol
(cortisol at time 0 min relative to baseline; − 60 min) associ-
ated with experimental stress exposure was greatest in HC
controls and least in CHR-P patients, with CHR-CBD patients
exhibiting an intermediate response (Fig. 2). Planned contrasts
revealed that the cortisol reactivity was significantly different
(t(54) = 3.08, p = .003; HC v CHR-P mean difference =
117.67, 95% CI 25.45–209.88, d = 1.31) in HC (M =
77.08 nmol/L, s.d. = 122.54) compared with CHR-P (M = −
40.59 nmol/L, s.d. = 136.98), and in HC compared with CHR-
CBD (M = − 23.67, s.d. = 99.82; t(54) = 2.53, p = .014, mean
difference = 100.75, 95% CI 4.94–196.55, d = 0.90) but was
not different between CHR-P and CHR-CBD (t(54) = − .39,
p = .70, mean difference = 16.92, 95% CI − 86.99–120.84,
d = 0.14)).
Anxiety reactions to acute stress induction with TSST
There was a significant effect of group (HC, CHR-P, CHR-
CBD F(2,43) = 3.68, p = .034) on STAI-S AUC scores.
Across the three participant groups, there was a significant
(F(1,43) = 6.85, p = .012) linear increase in STAI-S scores,
indicating that the experience of anxiety in response to the
TSST was greatest in CHR-P and least in HC, with CHR-
CBD exhibiting an intermediate response (Fig. 3). Planned
contrasts revealed that the STAI-S AUC was significantly dif-
ferent (t(43) = − 2.62, p = .01; HC v CHR-Pmean difference =
− 373.75, 95% CI − 720.52–− 26.98, d = 0.92) in HC (M =
1428.33, s.d. = 413.26) compared with CHR-P(M = 1802.08,
s.d. = 397.16), but not when compared with CHR-CBD (M =
1656.54, s.d. = 359.41, t(43) = −1.64, p = .11; HC v CHR-
CBD mean difference = −228.21, 95% CI − 566.38–109.97,
d = 0.59) and was also not different between CHR-P and
CHR-CBD (t(43) = − .92, p = .36, mean difference = −
145.54, 95% CI − 529.16–238.07, d = 0.38) (see Fig. 3).
Effect of acute stress on negative self-statements
There was a significant effect of group (HC, CHR-P, CHR-
CBD F(2,44) = 4.57, p = .016) on SSDPS-N AUC scores.
There was a significantF(1,44) = 9.11, p = .004 linear increase
in SSDPS-N AUC scores indicating that the experience of
negative statements was greatest in CHR-P, and least in HC,
with CHR-CBD patients exhibiting an intermediate response.
Planned contrasts revealed that the SSDPS-N was significant-
ly different (t(44) = − 1.07, p = .004; HC v CHR-P mean dif-
ference = − 169.36, 95% CI − 309.01–− 29.71, d = 0.94) in
HC (M = 333.50, s.d. = 135.82) compared with CHR-P (M =
502.86, s.d. = 217.12), but not when compared with CHR-
CBD (M = 394.62, s.d. 121.58; t(44) = −1.12, p = .27; mean
difference = − 61.12, 95% CI − 203.89–81.66, d = 0.47) and
Table 2 Descriptives for reactions to stress
Before drug administration Baseline 0 min + 10 min + 20 min
Cortisol levels (nmol/L) M s.d. M s.d. M s.d. M s.d. M s.d.
CHR-CBD 406.87 107.02 397.15 117.9 365.67 132.94 366.54 128.16 322.71 118.11
CHR-P 363.82 134.02 343.47 121.02 297.47 115.07 298.73 137.77 274.27 125.76
Healthy control NA NA 369.92 162.29 447 178.34 420.72 175.83 390.8 171.31
STAI scores M s.d. M s.d. M s.d. M s.d. M s.d.
CHR-CBD 39.57 9.33 37.33 8.66 44.31 11.11 42.62 10.7 43 12.44
CHR-P 41.07 8.78 38.07 10.21 48.31 11.53 44 10.82 41.13 10.76
Healthy control NA NA 32.87 10.27 40.33 13.18 34.79 11.17 31.87 10.79
SSDPS-N scores M s.d. M s.d. M s.d. M s.d. M s.d.
CHR-CBD NA NA 9.27 3.94 10.77 3.59 10.54 3.8 10.5 5.36
CHR-P NA NA 10.79 4.66 13.47 5.98 13.07 6.20 11.93 5.41
Healthy control NA NA 8 2.88 9.42 4.74 8.14 3.27 7.73 3.47
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approached a significant difference between CHR-P and
CHR-CBD (t(44) = − 1.75, p = .088 mean difference =
108.24, 95% CI − 46.12–262.60, d = 0.62).
Discussion
The first aim of the study was to investigate whether CHR
patients responded differently to a social stress paradigm com-
pared with healthy controls. The second aim was to assess
whether a 7-day treatment with CBD would attenuate the
acute effects of exposure to social stress.
As expected, we found that CHR patients under placebo
treatment (CHR-P) had a blunted cortisol response to the Trier
Social Stress Test (TSST) compared with healthy controls
(HC). Blunted cortisol response to experimental stress in
CHR-P compared with HC reported here is consistent with
previous reports in CHR individuals (Pruessner et al. 2013)
and in those with established psychosis (Jansen et al. 1998).
Our report extended these previous results in CHR partici-
pants by showing that blunted cortisol response to experimen-
tal stress was also associated with a greater psychological
response in terms of anxiety and perception of public speaking
as stressful in CHR-P compared with HC participants.
In line with our main hypothesis, we also found that CHR-
CBD displayed intermediate levels of neuroendocrine (corti-
sol reactivity) and psychological [anxiety and perception of
stress (negative self-statements)] response to experimental
stress comparedwith CHR-P and HC. Collectively, these find-
ings suggest that CHR participants under placebo displayed
abnormal neuroendocrine and psychological responses to ex-
perimental stress compared with HC participants, and that 7-
day treatment with CBD may potentially help partially atten-
uate these altered responses to experimental stress in CHR
participants. However, one needs to be cautious in considering
this interpretation, as the significant linear relationship across
the 3 participant groups was mainly driven by the significant
difference between HC and CHR-P on these measures.
Therefore, further research is needed to investigate whether
Fig. 2 Group-dependent cortisol
reaction
Fig. 3 Group-dependent experience of anxiety
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CBD may be used to influence the stress response in early
psychosis. Differences in cortisol reactivity and anxiety re-
sponse to stress in pairwise comparisons between CHR-P
and CHR-CBDwere not statistically significant, although this
difference approached significancewhen change in perception
of stress (negative self-statements) was compared between
them. Future longitudinal studies in larger samples taking into
account confounders are necessary to independently confirm
whether CBD treatment can significantly attenuate altered re-
sponses to experimental stress in CHR participants relative to
placebo treatment.
Nevertheless, our results provide preliminary evidence that
CBD may affect the altered neuroendocrine as well as the
psychological responses to acute stress in daily life in CHR
patients. Therefore, in contrast to atypical antipsychotics,
which have been shown to reduce elevated diurnal cortisol
levels (Zhang et al. 2005; Cohrs et al. 2006; Mondelli et al.
2010), but not correct the blunted cortisol response observed
in psychosis (Mondelli et al. 2010), CBD may potentially
attenuate abnormalities in some of the main components of
the acute stress response in the CHR state, future research
using larger samples would be required to confirm this sug-
gestion. These results are in line with previous research, which
suggests that CBD may have anxiolytic (Bergamaschi et al.
2011b) and antipsychotic effects (Bhattacharyya et al. 2018;
Leweke et al. 2012; McGuire et al. 2017).
The mechanism underlying the potential anti-stress effect
of CBD is currently unclear, with multiple potential mecha-
nisms being posited. Antipsychotic effects of CBD have been
linked to its effects on levels of the endogenous cannabinoid
anandamide (AEA) potentially by inhibiting its catalytic en-
zyme fatty acid amide hydrolase (FAAH). Recent preclinical
work has also suggested that CBD may block the anxiogenic
effects of chronic stress that was associated with a concomi-
tant decrease in the expression of FAAH following CBD treat-
ment (Fogaça et al. 2018). Anxiolytic effects of CBD were
blocked by cannabinoid receptor (type 1 and type 2) antago-
nists but not by the serotonergic 5HT-1A receptor antagonist.
However, other preclinical work suggests an effect of CBD on
5-HT1a receptors (Fogaça et al. 2016; Bih et al. 2015; Russo
et al. 2005) may underlie its anxiolytic effects.
To the best of our knowledge, this is the first study to have
investigated the effects of short-term treatment with CBD on
experimentally induced stress in the context of psychosis risk.
We employed a well-validated stress induction task that has a
long history (Kudielka et al. 2007a) of use for experimental
stress induction. This experimental stress paradigm employed
social evaluative stress, which may arguably be considered
more similar to the kind of life-stress that has been linked with
psychosis. While the use of a laboratory task may undermine
ecological validity compared with other approaches such as
experience sampling techniques, it does allow for more strin-
gent control and standardised stress exposure. Furthermore,
the task of speaking in public can be said to be life-like in that
it is formed as part of a mock job interview, which is a situa-
tion that most people who experience it perceive as stressful.
Further, in the healthy population sample, we recruited partic-
ipants such that they were matched to the at-risk participants.
However, these strengths and the results presented herein
need to be considered in light of certain caveats. In particular,
we were only able to investigate a relatively modest sample
size, which may have affected our ability to detect significant
difference between CHR-P and CHR-CBD in pairwise com-
parisons as well as potential generalisability of these results.
Previous studies of a similar nature have employed between
10 and 35 participants (Jansen et al. 1998; Jansen et al. 2000;
van Venrooij et al. 2012). Related to this, it may be argued that
the dose of CBD employed by us also affected our ability to
detect an anxiolytic effect of CBD. A recent study found an
anxiolytic effect of an acute dose of CBD at 300 mg but not at
100 or 900 mg (Zuardi et al. 2017), suggesting an inverted U-
shaped dose response. However, a previous study
(Bergamaschi et al. 2011b) also reported an anxiolytic effect
during an experimental public speaking task in patients with
social phobia, following a dose of 600 mg of CBD, a dose that
we have employed.
Furthermore, in this study, we used venous blood sampling,
which in itself can be quite stressful. However, in order to
mitigate the effects of venepuncture, we used an atraumatic
needle and employed an intravenous cannula that enabled us
to avoid repeated venepuncture. While we cannot completely
rule out the possibility that the stress of venepuncture may
have added to the stress of participants, we do not believe that
this would have confounded our results as such stress would
have acted across all participants and only added to the social
evaluative stress induced by the public speaking task, thereby
contributing to how stressed participants felt overall.
Furthermore, there was a gap of approximately 50 min be-
tween venepuncture and stress exposure, by which time any
effects of stress from the venepuncture would have reduced
substantially.
It is also important to note several additional factors may
also have affected cortisol response to the Trier Social Stress
Test (TSST), which were not controlled for in this study, in-
cluding body mass index (Bose et al. 2009), night-shift work
(Kudielka et al. 2007b), menstrual cycle and the use of con-
traceptives (Kirschbaum et al. 1999). However, gender distri-
butions between the groups were not significantly different
and participants were randomly allocated to the two treatment
groups, making it likely that these effects would have affected
the study groups to a similar extent. The cortisol levels could
also have been affected by individual differences in the diurnal
decline of the cortisol slope, but as the CBD and placebo
group were randomised, it is reasonable to conclude that these
differences would be equal between these groups.
Furthermore, in a previous study (Collip et al. 2011), it has
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been shown that the diurnal slope did not differ between
healthy controls and those at above average genetic risk for
psychosis. The procedure we used for the TSSTmay also have
been insufficient to distinguish between anticipatory and re-
active cortisol. The baseline sample was taken 60 min before
the onset of the stressor and the first sample after was taken
20 min after stressor onset. Previous studies have suggested
that anticipatory cortisol levels may provide information when
considering differences in mental health and protocols have
been developed to capture this (Engert et al. 2013). Similarly,
we measured cortisol levels up to 20 min after the stressful
task concluded. It is agreed that cortisol levels reach a peak
within 20–30 min after a stressor onset and that they return
back to baseline levels within 90min of cessation of the stress-
or (Fink 2000). The first sample after cessation of the stressor
represents 20 min after the onset of the stressor; therefore, the
+ 10-min sample represents 30 min after and + 20 min repre-
sents 40 min after the onset of the stressor. It is therefore
possible that the sampling is picking up anticipatory cortisol
reactions and not reactive cortisol. However, the 0-min corti-
sol samples immediately after the TSST represents 20 min
after onset of the stressor and cortisol levels in the healthy
control group peak at this point and then continue to reduce,
it is possible that this sample is still picking up reactive corti-
sol. It should also be noted that it has been found that high
schizotypes have been found to have a delayed cortisol re-
sponse (Walter et al. 2018). However, in this study, the peak
of the cortisol response was at 15 min after the cessation of the
TSST in both high and low schizotypes, and the delay was in
the anticipatory rise. High schizotypes had no rise until 15min
after the cessation of the TSST whereas the low schizotypes
had a rise immediately before the TSST commenced. While it
is possible due to the sampling procedure, we may have
missed the cortisol peak for the CHR participants, this is
unlikely given the last sample is taken a full 40 min after the
stressor commenced and no peak is seen in our data. Future
research should follow the protocol outlined by Engert et al.
(2013) and ensure adequate sampling is taken both in antici-
pation of the TSST and after the TSST to fully assess the
increase and decrease of cortisol in response to stress. In any
case, the conclusions of this study that CBD may have a po-
tential to affect cortisol in response to stress is still a
possibility.
It could also be argued that education level may affect
how stressful the participants found the task, while educa-
tion level was lower in CHR compared with HC, it was not
different between the CBD and placebo groups, making it
unlikely that our conclusions would be affect by this
difference.
Notwithstanding its limitations, the present study provides
a strong rationale for future studies to investigate whether
CBD may have potential to mitigate the harmful effects of
stress in the course of daily life by attenuating the altered
neuroendocrine and psychological responses to acute stress
in CHR participants.
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